Pharmacoeconomic review report: Buprenorphine extended-release injection (Sublocade) (Indivior Canada, Ltd.) indication, for the management of moderate-to-severe opioid use disorder in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product

Buprenorphine extended-release injection (BUP-ER; Sublocade) is indicated for the management of moderate-to-severe opioid use disorder (OUD) in adult patients who have been inducted and clinically stabilized on the equivalent of 8 mg per day to 24 mg per day of transmucosal buprenorphine-containing...

Full description

Bibliographic Details

Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health July 2019, 2019
Edition:	Version: Final
Series:	CADTH common drug review
Subjects:	Adult Canada Buprenorphine / Therapeutic Use Opiate Substitution Treatment / Economics Cost-benefit Analysis Methadone / Therapeutic Use Opioid-related Disorders / Drug Therapy Treatment Outcome
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK546358
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa